Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Erste Group Bank increased their FY2026 earnings per share (EPS) estimates for Gilead Sciences in a research note issued to investors on Thursday, August 27th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn ($0.45) per share for the year, up from their prior estimate of ($0.75). The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.50) per share. Erste Group Bank also issued estimates for Gilead Sciences’ FY2027 earnings at $9.86 EPS.
GILD has been the subject of several other reports. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Morgan Stanley dropped their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $158.04.
Gilead Sciences Price Performance
Shares of NASDAQ:GILD opened at $146.34 on Tuesday. The firm’s 50 day moving average price is $134.68 and its 200-day moving average price is $136.50. Gilead Sciences has a twelve month low of $108.46 and a twelve month high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $181.46 billion, a PE ratio of -54.81 and a beta of 0.32.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the company posted $2.01 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year.
Institutional Trading of Gilead Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its position in shares of Gilead Sciences by 12,498.3% during the second quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company’s stock valued at $30,469,248,000 after buying an additional 239,254,365 shares during the last quarter. BlackRock Inc. bought a new position in shares of Gilead Sciences during the second quarter worth $15,393,785,000. State Street Corp grew its stake in Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after acquiring an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after acquiring an additional 1,195,269 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Gilead Sciences by 15.2% in the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.
Insider Transactions at Gilead Sciences
In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. This represents a 19.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 90,000 shares of company stock valued at $12,266,220. Company insiders own 0.30% of the company’s stock.
Gilead Sciences Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently -122.85%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
